|Bid||73.87 x 800|
|Ask||75.00 x 900|
|Day's Range||73.54 - 77.32|
|52 Week Range||8.90 - 189.89|
|Beta (5Y Monthly)||1.62|
|PE Ratio (TTM)||8.38|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Investors might have begun to worry that Fulgent Genetics' (NASDAQ: FLGT) freefall in recent months would never end. The genetic testing company's shares have plunged more than 50% from the highs set earlier this year. Fulgent announced its first-quarter results after the market closed Thursday.
At this time, I would like to turn the conference over to Nicole Borsje with investor relations. On the call today are Ming Hsieh, chief executive officer; Paul Kim, chief financial officer; and Brandon Perthuis, chief commercial officer.
Shares of genetic testing company Fulgent Genetics (NASDAQ: FLGT) fell 20% in April, according to data from S&P Global Market Intelligence. The success in rolling out COVID-19 vaccines has been the driver of Fulgent's continued sell-off this past month. In the fourth quarter, nearly 90% of revenue came from COVID-19 testing as opposed to Fulgent's core genetic testing.